Summary
Johnson & Johnson reported strong performance in the third quarter of fiscal year 2012, with worldwide sales increasing by 6.5% to $17.1 billion compared to the prior year period. This growth was driven by significant operational improvements across all segments, particularly in Medical Devices and Diagnostics (up 12.5%) and Pharmaceuticals (up 7.0%). The company also saw a robust increase in U.S. sales across segments. Net earnings attributable to Johnson & Johnson for the quarter were $2.97 billion, a decrease from the prior year's $3.20 billion, primarily due to an $700 million in-process research and development charge related to the discontinuation of bapineuzumab IV. Despite this charge, the company demonstrated solid operational execution and strategic progress. The nine-month period ending September 30, 2012, showed worldwide sales of $49.7 billion, a 1.8% increase. Net earnings attributable to Johnson & Johnson for this period were $8.29 billion, a decrease from $9.45 billion in the prior year, also impacted by significant charges including $1.1 billion for in-process R&D and intangible asset write-downs. The acquisition of Synthes, Inc. for $20.2 billion in cash and stock, completed in the second quarter, is a significant strategic move expected to bolster the Medical Devices and Diagnostics segment. Management remains focused on cost containment and strategic investments despite ongoing litigation and regulatory scrutiny.
Key Highlights
- 1Worldwide sales increased by 6.5% to $17.1 billion in Q3 2012, driven by strong operational growth across all segments.
- 2The Medical Devices and Diagnostics segment showed robust growth of 12.5%, significantly boosted by the Synthes acquisition.
- 3Pharmaceutical segment sales grew by 7.0%, with strong performance in Immunology and Oncology therapeutic areas.
- 4Net earnings attributable to Johnson & Johnson for Q3 2012 were $2.97 billion, impacted by a $700 million in-process R&D charge.
- 5The company completed the significant acquisition of Synthes, Inc. for $20.2 billion in cash and stock during the second quarter.
- 6Operating profit margins showed resilience across segments, with Medical Devices and Diagnostics showing improved profitability compared to the prior year.
- 7Johnson & Johnson continues to manage its liquidity effectively, with operating cash flows remaining strong despite significant investments and debt retirement.